(Q37901534)

25 August 2017

1 reference

title

Posaconazole: when and how? The clinician's view (English)

1 reference

25 August 2017

1 reference

ChEBI release 2020-05-28

3

Emmanuel Roilides

1 reference

25 August 2017

4

Theoklis E Zaoutis

1 reference

25 August 2017

Aspasia Katragkou

1

1 reference

25 August 2017

Fotini Tsikopoulou

series ordinal

2

1 reference

25 August 2017

publication date

18 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

55

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

110-122

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Epidemiology of invasive candidiasis: a persistent public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

The changing face of epidemiology of invasive fungal disease in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Infections due to emerging and uncommon medically important fungal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Synergistic effect of posaconazole and caspofungin against clinical zygomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Antifungal therapy of murine Aspergillus terreus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Efficacy and safety of posaconazole for chronic pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Sinus zygomycosis in a patient receiving voriconazole prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Current experience in treating invasive zygomycosis with posaconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Activity of posaconazole in the treatment of central nervous system fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole therapy for chronic refractory coccidioidomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole salvage treatment in paediatric patients: a multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole for treatment of refractory invasive fungal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole for paediatric patients: status of development and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacokinetic/pharmacodynamic profile of posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Omeprazole significantly reduces posaconazole serum trough level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Antifungal therapeutic drug monitoring: established and emerging indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2011.02061.X

10.1111/J.1439-0507.2011.02061.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference